NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 248 filers reported holding NEKTAR THERAPEUTICS in Q4 2020. The put-call ratio across all filers is 0.43 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $1 | -98.2% | 1,293 | -98.4% | 0.00% | – |
| Q1 2023 | $57 | -78.2% | 81,400 | -29.4% | 0.00% | – |
| Q4 2022 | $261 | -99.9% | 115,300 | 0.0% | 0.00% | -100.0% |
| Q3 2022 | $369,000 | -4.9% | 115,300 | +13.0% | 0.00% | 0.0% |
| Q2 2022 | $388,000 | -64.0% | 102,044 | -49.0% | 0.00% | 0.0% |
| Q1 2022 | $1,078,000 | -60.2% | 200,000 | -0.3% | 0.00% | -66.7% |
| Q4 2021 | $2,711,000 | -24.8% | 200,663 | -0.1% | 0.00% | -25.0% |
| Q3 2021 | $3,606,000 | +5.1% | 200,778 | +0.4% | 0.00% | 0.0% |
| Q2 2021 | $3,432,000 | -11.5% | 200,000 | +3.2% | 0.00% | 0.0% |
| Q1 2021 | $3,876,000 | -0.6% | 193,800 | -15.5% | 0.00% | 0.0% |
| Q4 2020 | $3,898,000 | -6.0% | 229,300 | -8.3% | 0.00% | -20.0% |
| Q3 2020 | $4,148,000 | -36.4% | 250,000 | -11.3% | 0.01% | -37.5% |
| Q2 2020 | $6,526,000 | +24.9% | 281,800 | -3.7% | 0.01% | 0.0% |
| Q1 2020 | $5,223,000 | -17.3% | 292,600 | 0.0% | 0.01% | 0.0% |
| Q4 2019 | $6,316,000 | +14.6% | 292,600 | -3.3% | 0.01% | +14.3% |
| Q3 2019 | $5,512,000 | -50.3% | 302,600 | -2.9% | 0.01% | -50.0% |
| Q2 2019 | $11,087,000 | +11.9% | 311,600 | +5.6% | 0.01% | +7.7% |
| Q1 2019 | $9,912,000 | +0.5% | 295,000 | -1.6% | 0.01% | -7.1% |
| Q4 2018 | $9,858,000 | -48.4% | 299,900 | -4.3% | 0.01% | -39.1% |
| Q3 2018 | $19,105,000 | +25.4% | 313,400 | +0.5% | 0.02% | +21.1% |
| Q2 2018 | $15,233,000 | -15.3% | 311,960 | +84.4% | 0.02% | -13.6% |
| Q1 2018 | $17,980,000 | +77.3% | 169,210 | -0.3% | 0.02% | +83.3% |
| Q4 2017 | $10,140,000 | +101.9% | 169,785 | -18.9% | 0.01% | +100.0% |
| Q3 2017 | $5,022,000 | -7.3% | 209,269 | -24.5% | 0.01% | -14.3% |
| Q2 2017 | $5,419,000 | +15.0% | 277,184 | +38.0% | 0.01% | +16.7% |
| Q1 2017 | $4,713,000 | +90.3% | 200,828 | -0.5% | 0.01% | +50.0% |
| Q4 2016 | $2,476,000 | -24.0% | 201,759 | +6.4% | 0.00% | -20.0% |
| Q3 2016 | $3,259,000 | +19.9% | 189,677 | -0.7% | 0.01% | +25.0% |
| Q2 2016 | $2,719,000 | +9.5% | 191,047 | +5.8% | 0.00% | 0.0% |
| Q1 2016 | $2,482,000 | -16.9% | 180,527 | +1.9% | 0.00% | -20.0% |
| Q4 2015 | $2,985,000 | +56.7% | 177,127 | +1.9% | 0.01% | +66.7% |
| Q3 2015 | $1,905,000 | -17.2% | 173,827 | -5.6% | 0.00% | 0.0% |
| Q2 2015 | $2,302,000 | +328.7% | 184,047 | +276.9% | 0.00% | +200.0% |
| Q1 2015 | $537,000 | -76.4% | 48,827 | -75.7% | 0.00% | -75.0% |
| Q4 2013 | $2,280,000 | +8.6% | 200,850 | 0.0% | 0.00% | 0.0% |
| Q3 2013 | $2,099,000 | – | 200,850 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Camber Capital Management LP | 3,500,000 | $60,060,000 | 2.02% |
| ACT CAPITAL MANAGEMENT, LLC | 161,500 | $2,772,000 | 1.42% |
| Rhenman & Partners Asset Management AB | 950,000 | $16,302,000 | 1.11% |
| MAVERICK CAPITAL LTD | 5,761,073 | $98,860,000 | 0.93% |
| Birchview Capital, LP | 72,000 | $1,236,000 | 0.74% |
| Bellevue Group AG | 4,101,404 | $70,380,000 | 0.69% |
| CM Management, LLC | 50,000 | $858,000 | 0.62% |
| Duquesne Family Office | 1,000,000 | $17,160,000 | 0.42% |
| OSTERWEIS CAPITAL MANAGEMENT INC | 373,368 | $6,407,000 | 0.33% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 67,000 | $1,149,000 | 0.30% |